FZD7

Across TCGA pan-cancer cohorts, FZD7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FZD7 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FZD7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FZD7 expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where FZD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.443	0.873	.003	18	view →
HNSC	OS	Median	All	0.778	0.941	.006	7	view →
LUAD	OS	Median	III,IV	0.420	1.000	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FZD7–PDAC (DFS)

Open the PDAC breakdown →